What is emgality used for?

What other conditions is Emgality approved to treat?

Emgality is approved by the FDA to prevent migraine in adults and to treat episodic cluster headache in adults.

What does the FDA specifically say about its use in migraines?

The FDA approved Emgality for migraine prevention in adults in 2018. It belongs to the class of drugs called calcitonin gene-related peptide antagonists, or CGRP antagonists.

What happens if you stop taking Emgality?

Stopping treatment may lead to migraine attacks returning. Patients typically receive a loading dose followed by monthly maintenance injections.

How does Emgality compare with other CGRP inhibitors?

Emgality differs from other CGRP inhibitors in its dosing schedule and approved indications. Some drugs in this class have monthly or quarterly dosing options.

When does Emgality's patent expire?

Emgality's patent expires in 2034.